Publications

Export 6470 results:
Sort by: Author [ Title  (Asc)] Type Year
A B C D E F G H I J K L M N [O] P Q R S T U V W X Y Z   [Show ALL]
A
Ohmura, S., K. Nagaya, F. Shimojo, and M. Yao, "Ab Initio MOLECULAR-DYNAMICS STUDY OF NONEQUILIBRIUM PHENOMENA IN DISORDERED MATERIALS", MODELS IN BIOSCIENCE AND MATERIALS RESEARCH, pp. 1, Submitted. Abstract
n/a
Ohmura, S., K. Nagaya, F. Shimojo, and M. Yao, "Ab Initio MOLECULAR-DYNAMICS STUDY OF NONEQUILIBRIUM PHENOMENA IN DISORDERED MATERIALS", MODELS IN BIOSCIENCE AND MATERIALS RESEARCH, pp. 1, Submitted. Abstract
n/a
Eissa, M., Y. El Miedany, W. Hassan, D. Mekkawy, M. A. Mortada, S. I. Nasef, M. El Gaafary, hala lotfy, yomna farag, G. El Deriny, et al., AB0962 UPDATE FOR THE CLINICAL PRACTICE: INTEGRATED, EVIDENCE-BASED APPROACH FOR THE MANAGEMENT OF JUVENILE SPONDYLOARTHRITIS, : BMJ Publishing Group Ltd, 2019. Abstract
n/a
Eissa, M., Y. El Miedany, W. Hassan, D. Mekkawy, M. A. Mortada, S. I. Nasef, M. El Gaafary, hala lotfy, yomna farag, G. El Deriny, et al., AB0962 UPDATE FOR THE CLINICAL PRACTICE: INTEGRATED, EVIDENCE-BASED APPROACH FOR THE MANAGEMENT OF JUVENILE SPONDYLOARTHRITIS, : BMJ Publishing Group Ltd, 2019. Abstract
n/a
Eissa, M., Y. El Miedany, W. Hassan, D. Mekkawy, M. A. Mortada, S. I. Nasef, M. El Gaafary, hala lotfy, yomna farag, G. El Deriny, et al., AB0962 UPDATE FOR THE CLINICAL PRACTICE: INTEGRATED, EVIDENCE-BASED APPROACH FOR THE MANAGEMENT OF JUVENILE SPONDYLOARTHRITIS, : BMJ Publishing Group Ltd, 2019. Abstract
n/a
Selby, S., N. O’Sullivan, D. Edgeworth, M. Hashim, and D. Harmon, AB100. 11. Patient’s perceptions of Green Exercise, in the setting of chronic pain, , vol. 2, pp. AB100 - AB100, 2018/02/01. Abstract
n/a
Selby, S., N. O’Sullivan, D. Edgeworth, M. Hashim, and D. Harmon, AB100. 11. Patient’s perceptions of Green Exercise, in the setting of chronic pain, , vol. 2, pp. AB100 - AB100, 2018/02/01. Abstract
n/a
Abe, M., T. Abe, B. Abed-Ashtiani, M. G. Abele, R. Acebal, T. Adachi, T. C. Aden, A. A. Adly, K. Agarwal, S. Agarwal, et al., Abarra, EN, see Yamada, Y., T-MAG Sep 97 3622-3624 Abdullah, F., see Khan, SH, T-MAG Mar 97 2081-2084 Abe, I., see Muraoka, H., T-MAG Sep 97 2929-2931 Abe, M., see Takada, A., T-MAG Sep 97 2932-2934, , Submitted. Abstract
n/a
Asnafi, N., T. Balakrishna Bhat, Z. Ben-Liam, T. Besshi, B. Carlsson, C. S. Chang, S. L. Chen, A. P. Cherrill, J. S. Choi, J. Danckert, et al., "Abdel-Hamid, A., 97", Journal of Materials Processing Technology, vol. 73, pp. 303, 1998. Abstract
n/a
Abe, M., L. Abelmann, B. R. Acharya, S. Acharya, O. Acher, A. L. Adenot, S. Adenwalla, A. A. Adly, U. Adriano, M. Ahmadian, et al., Abe, M., AI Shames, N. Matsushita, and Y. Shimada. Ferromagnetic resonance study on magnetic homogeneity in spin-sprayed NiZn ferrite films highly permeable at gigahertz frequencies; T-MAG Sep 03 3142-3144, , Submitted. Abstract
n/a
Mansour, W. Y., N. V. Bogdanova, U. Kasten-Pisula, T. Rieckmann, S. Köcher, K. Borgmann, M. Baumann, M. Krause, C. Petersen, H. Hu, et al., "Aberrant overexpression of miR-421 downregulates ATM and leads to a pronounced DSB repair defect and clinical hypersensitivity in SKX squamous cell carcinoma", Radiotherapy and oncology, vol. 106, no. 1: Elsevier, pp. 147–154, 2013. Abstract
n/a
El-Mougy, F. A., M. M. Yusuf, D. A. Omran, and S. A. Sharaf, "Aberrant p16INK4A methylation: Relation to viral related", South Asian journal of cancer, vol. 3, issue 1, pp. 1-4, 2014. southasianjcancer311-6131332_170153.pdf
El-Mougy, F. A., M. M. Youssef, D. A. Omran, S. A. Sharaf, H. H. El-Sayed, W. A. Rabie, and Elghobary A. Mohamed, "Aberrant p16INK4A methylation: Relation to viral related chronic liver disease and hepatocellular carcinoma", South Asian J Cancer. , vol. 3, issue 1, pp. 1-4, 2014.
El-Mougy, F. A., M. M. Youssef, D. A. Omran, S. A. Sharaf, H. H. El-Sayed, W. A. Rabie, and E. A. Mohame, Aberrant p16INK4A methylation: Relation to viral related chronic liver disease and hepatocellular carcinoma, , 2014.
El-Mougy, F. A., M. M. Youssef, D. A. Omran, S. A. Sharaf, H. H. El-Sayed, W. A. Rabie, E. A. Mohamed, and H. A. Elghobary, "Aberrant p16INK4A methylation: Relation to viral related chronic liver disease and hepatocellular carcinoma.", South Asian journal of cancer, vol. 3, issue 1, pp. 1-4, 2014 Jan. Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is currently the fifth most common solid tumor worldwide and the third leading cause of cancer related deaths. Several studies have shown that the tumor suppressor gene p16INK4A is frequently downregulated by aberrant methylation of the 5'-cytosine-phosphoguanine island within the promoter region.

AIM: To find out the frequency of methylated p16INK4A in the peripheral blood of HCC and cirrhotic patients and to evaluate its role in hepatocarcinogenesis.

PATIENTS AND METHODS: This study was performed on 58 subjects: 30 HCC patients, 20 cirrhotic patients, and eight healthy volunteers. Methylation of p16INK4A was examined using methylation specific polymerase chain reaction (PCR) (MSP). Comparison of quantitative variables between the study groups was done using Mann-Whitney U test for independent samples when not normally distributed. For comparing categorical data, Chi-square (χ(2)) test was performed. Exact test was used instead when the expected frequency was less than 5.

RESULTS: Methylation of p16INK4A was found in 6.7% of HCC patients, 5% of liver cirrhosis (LC) patients, and none of the healthy volunteers; 66.67% of the p16INK4A-methylated cases (2/3) were positive for anti-hepatitis C virus (HCV) antibodies (one of them had HCC). All HCC cases with aberrant p16INK4A methylation show very high serum alpha fetoprotein (AFP) level (9,080; 30,000 μg/mL). There were no significant associations between the status of p16INK4A methylation and tumor size.

CONCLUSION: Hypermethylation of p16INK4A was found to be infrequent among Egyptian patients with HCC.

El-Mougy, F. A., M. M. Youssef, D. A. Omran, S. A. Sharaf, H. H. El-Sayed, W. A. Rabie, E. A. Mohamed, and H. A. Elghobary, "Aberrant p16INK4A methylation: Relation to viral related chronic liver disease and hepatocellular carcinoma.", South Asian J Cancer, vol. 3, pp. 1-4, 2014.
El-Mougy, F. A., M. M. Youssef, D. A. Omran, S. A. Sharaf, H. H. El-Sayed, W. A. Rabie, E. A. Mohamed, and H. A. Elghobary, "Aberrant p16INK4A methylation: Relation to viral related chronic liver disease and hepatocellular carcinoma.", South Asian journal of cancer, vol. 3, issue 1, pp. 1-4, 2014. Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is currently the fifth most common solid tumor worldwide and the third leading cause of cancer related deaths. Several studies have shown that the tumor suppressor gene p16INK4A is frequently downregulated by aberrant methylation of the 5'-cytosine-phosphoguanine island within the promoter region.

AIM: To find out the frequency of methylated p16INK4A in the peripheral blood of HCC and cirrhotic patients and to evaluate its role in hepatocarcinogenesis.

PATIENTS AND METHODS: This study was performed on 58 subjects: 30 HCC patients, 20 cirrhotic patients, and eight healthy volunteers. Methylation of p16INK4A was examined using methylation specific polymerase chain reaction (PCR) (MSP). Comparison of quantitative variables between the study groups was done using Mann-Whitney U test for independent samples when not normally distributed. For comparing categorical data, Chi-square (χ(2)) test was performed. Exact test was used instead when the expected frequency was less than 5.

RESULTS: Methylation of p16INK4A was found in 6.7% of HCC patients, 5% of liver cirrhosis (LC) patients, and none of the healthy volunteers; 66.67% of the p16INK4A-methylated cases (2/3) were positive for anti-hepatitis C virus (HCV) antibodies (one of them had HCC). All HCC cases with aberrant p16INK4A methylation show very high serum alpha fetoprotein (AFP) level (9,080; 30,000 μg/mL). There were no significant associations between the status of p16INK4A methylation and tumor size.

CONCLUSION: Hypermethylation of p16INK4A was found to be infrequent among Egyptian patients with HCC.

Elhamid, B. A., mohamed emam, M. Mostafa, A. Hasanin, W. Awada, A. Rady, and H. Omar, "The ability of perfusion index to detect segmental ulnar nerve sparing after supraclavicular nerve block", Journal of Clinical Monitoring and Computing, vol. 34, pp. 1185-1191, 2020.
Abdelhamid, B., M. Emam, M. Mostafa, A. Hasanin, W. Awada, A. Rady, and H. Omar, "The ability of perfusion index to detect segmental ulnar nerve sparing after supraclavicular nerve block", Journal of Clinical Monitoring and Computing, vol. 34, issue 6: Springer Science and Business Media B.V., pp. 1185 - 1191, 2020. AbstractWebsite
n/a
Elhamid, B. A., mohamed emam, M. Mostafa, A. Hasanin, W. Awada, A. Rady, and H. Omar, "The ability of perfusion index to detect segmental ulnar nerve sparing after supraclavicular nerve block.", Journal of clinical monitoring and computing, vol. 34, issue 6, pp. 1185-1191, 2020. Abstract

Supraclavicular nerve block (SCB) is a commonly used regional block for upper extremity surgery. The most common form of failure of SCB is ulnar segmental sparing. We aimed to evaluate the accuracy of perfusion index (PI) in early detection of segmental sparing of the ulnar component of SCB. A prospective observational study included adult patients scheduled for surgery under ultrasound-guided SCB. PI was simultaneously measured at the index finger and little finger. PI was recorded every minute for the first 10 min after SCB. PI ratio was calculated at every measurement point as PI/baseline PI. The area under the receiver operating characteristic (AUROC) curve was calculated for the ability of PI ratio to detect segmental ulnar sparing with comparison of little finger readings to the index finger readings. Forty-nine patients were available for the final analysis. Nine patients (18%) had segmental ulnar sparing. PI ratio at the little finger showed excellent predictive ability for ulnar sparing starting from the fifth minute (AUROC 0.92 [0.8-0.98], cutoff value ≤ 1.71) and reached the highest value at the seventh minute (AUROC 0.96 [0.86-1], cutoff value ≤ 1.35), whereas PI ratio at the index finger showed poor predictive ability. When using the PI for evaluation of successful SCB, segmental ulnar sparing could be accurately detected when the PI was measured at the little finger and not at the index finger. An increase of 71% in PI at the little finger 5 min after SCB could accurately rule out ulnar sparing.Clinical trial identifier NCT03880201. Clinical trial registration https://clinicaltrials.gov/ct2/show/NCT03880201?term=NCT03880201&draw=2&rank=1 .

Ali, M. A., A. Assefa, D. Assefa, L. Bal{\'ık, A. Basu, O. Berger, E. Berhan, B. Beshah, E. Birhan, T. Buriánek, et al., "Abraham, Ajith 183, 293,303, 315, 371 Ahmed, Nada 315 Aldosari, Hamoud M. 303 Alhamedi, Adel H. 303", Afro-European Conference for Industrial Advancement: Proceedings of the First International Afro-European Conference for Industrial Advancement AECIA 2014, vol. 334: Springer, pp. 383, 2014. Abstract
n/a
Osman, S. A., and A. M. Aboul-Enein, "Absorption and distribution of 7-I131 Iodocholesterol in tissues of normal and hypercholesterolemic rats", Bull. Fac. Agric. Cairo Univ., , vol. XXVIII, pp. 339, 1977.
Kassem, L., S. Omarjee, S. Chabaud, E. Lavergne, C. Faure, F. Beurrier, O. Tredan, L. Corbo, I. Treilleux, and M. Le Romancer, Abstract P4-11-23: Membranous ERα-36 expression is an independent predictor of poor prognosis in operable breast cancer, : American Association for Cancer Research, 2015. Abstract
n/a
Gault, L. M., R. A. Lenz, C. W. Ritchie, A. Meier, A. A. Othman, Q. Tang, S. Berry, Y. Pritchett, and W. Z. Robieson, "ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.", Alzheimer's research & therapy, vol. 8, issue 1, pp. 44, 2016 Oct 18. AbstractWebsite

BACKGROUND: Results from a phase 2a study indicated that treatment with the novel α7 nicotinic acetylcholine receptor agonist ABT-126 25 mg once daily (QD) was associated with a trend for improvement in cognition in subjects with mild-to-moderate Alzheimer's dementia (AD). A phase 2b program was designed to evaluate a broader dose range of ABT-126 as monotherapy in subjects with mild-to-moderate AD. The program consisted of a double-blind, placebo and active controlled study of ABT-126 (dose range 25-75 mg) and an open-label extension study (75 mg).

METHODS: The randomized double-blind study enrolled 438 subjects (Mini-Mental Status Examination score of 10-24, inclusive) not currently taking acetylcholinesterase inhibitors or memantine. Subjects received 24 weeks of ABT-126 25 mg QD (n = 77), ABT-126 50 mg QD (n = 108), ABT-126 75 mg QD (n = 73), donepezil 10 mg QD (n = 76), or placebo (n = 104). The primary endpoint was the change from baseline to week 24 in the 11-item Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) total score. Subjects completing the double-blind study could enroll in the 28-week open-label extension study. Adverse events (AEs) and other safety parameters were monitored in both studies.

RESULTS: A total of 367 patients (83.8 %) completed the double-blind study and 349 (79.7 %) entered the open-label study. Compared with placebo, donepezil significantly improved ADAS-Cog 11-item total scores from baseline to week 24 (-2.29 ± 0.95; one-sided P = 0.008). No ABT-126 dose demonstrated a statistically significant improvement vs placebo at week 24 in the ADAS-Cog total score: ABT-126 25 mg, -0.47 ± 0.94 (P = 0.309); ABT-126 50 mg, -0.87 ± 0.85 (P = 0.153); and ABT-126 75 mg, -1.08 ± 0.94 (P = 0.127). Rates of serious AEs and discontinuations due to AEs were similar across treatment groups. The most frequently reported AEs in both studies were constipation, fall, and headache. No clinically meaningful changes were observed in other parameters.

CONCLUSIONS: In the double-blind trial, donepezil significantly improved ADAS-Cog scores but no statistically significant improvement was seen with any ABT-126 dose. ABT-126 had an acceptable safety profile in subjects with mild-to-moderate AD in both studies.

TRIAL REGISTRATION: ClinicalTrials.gov NCT01527916 , Registered 3 February 2012 (randomized trial). ClinicalTrials.gov NCT01676935 . Registered 29 August 2012 (open-label extension study).

Ding, Y., M. S. Osman, and A. - M. Wazwaz, "Abundant complex wave solutions for the nonautonomous Fokas-Lenells equation in presence of perturbation terms", Optik, vol. 181, pp. 503-513, 2019.
Tourism